Biorbis

Do IT and R&D work together as well as they should in your organization?

Confirmed Speakers
Dr Eric Perakslis Vice President, R&D IT and Corporate Office of Science and Technology Johnson & Johnson	Dr Sanjoy Ray Director, Technology Innovation Merck	Dr Enoch Huang Executive Director, Computational Sciences, Research Center of Emphasis Pfizer
Dr Adel Laoui Director, Healthcare Technologies Sanofi Aventis	Dr Deepak Rajpal Senior Scientific Investigator, Computational Biology, Drug Discovery GSK	Dr Julia Zhang Associate Director, Biomedical Data Sciences and Informatics Genzyme
Dr Rainer Fuchs Vice President, R&D Information Technologies Biogen Idec	Ted Slater Associate Director, Biology Systems and Knowledge Discovery Boehringer Ingelheim	Dr Birgit Schoeberl Vice President of Research Merrimack Pharmaceuticals
Dr Dmitri Mikhailov Lab Head, Lead Discovery Informatics, Center for Proteomic Chemistry Novartis	Dr Mark Trusheim Visiting Scientist and Executive-in-Residence, Sloan School of Management, MIT; Former, Special Government Employee at Office of the Commissioner FDA	Dr Ernst Dow Principal Research Scientist, LRL R&D IT Informatics Eli Lilly
Brian Claus Senior Research Investigator, Applied Biotechnologies and Computer-Assisted Drug Design Bristol-Myers Squibb	Dr Patrick Walters Senior Research Fellow, Group Head, Computational Drug Discovery Technologies Vertex Pharmaceuticals	Dr Lisa Garrard Director, Informatics and IT OncoMed Pharmaceuticals
Dr Peter Tonellato Director, Laboratory for Personalized Medicine and Senior Research Scientist, Center for Biomedical Informatics Harvard Medical School	Dr John Burke Associate Director, Systems Biology Boehringer Ingelheim
Rick Franckowiak, Information Technology Director, Pharmaceutical Research and Development, Johnson & Johnson Daniel Ingber, Senior Manager, Research Information Systems, MedImmune Dr Dominic Sinibaldi, Scientific Manager, Research Information Systems, MedImmune Dr John Burke, Associate Director, Systems Biology, Boehringer Ingelheim

The correct IT and informatics investment decisions can significantly increase your competitiveness in the global pharmaceutical marketplace. Being able to incorporate and interpret the vast amounts of data available to drive hypothesis driven drug development promises to:

• Improve target identification and lead validation
• Reduce research and development costs
• Reduce attrition rates by predicting efficacy and toxicity

The net result is an increase in R&D productivity and the depth and quality of your pipeline. But the challenge is knowing what the right technologies are to invest in and how to optimally incorporate IT and informatics into the drug discovery and development process.

Computational Drug Research and Development, in Boston 29th-30th September, has been designed in collaboration with Johnson & Johnson, Eli Lilly, MedImmune, Merck, Boehringer Ingelheim, Pfizer, Biogen Idec, GSK, Genzyme, Sanofi Aventis, Novartis, Bristol-Myers Squibb, Celgene, MIT and others to transform your ability to use computational methods in R&D. The meeting will bring together the technological innovators and R&D leaders from big pharma and biotech to explore how IT and informatics can rationalize the drug development process and increase your organization’s productivity.

Not to miss sessions:

• Learn how to successfully execute your technology strategy into drug development and increase your R&D productivity from J&J, Merck and Biogen Idec
• Generate new therapeutic hypotheses for disease by learning how to integrate biological, chemical and clinical resources to visualize the drug-target landscape from Pfizer
• Transform your drug discovery strategy using in silico methods for drug repositioning from GSK, computational methods for improved target selection from Eli Lilly and safety informatics for enhanced risk assessment in discovery phase from Novartis
• Explore how to apply systems biology to generate hypothesis driven models in drug discovery from Boehringer Ingelheim
• Build a customizable and robust scientific data warehouse for improved biomarker discovery with insights from MedImmune
• Achieve interoperability of lab data and explore best practices for integrating lab data into clinical trials from Genzyme
• Learn how to expand your R&D capabilities by using informatics and new technologies to enable a global consumer healthcare business model from Sanofi
• Understand how computer simulation and modeling can aid decision making in companion diagnostic development from MIT and FDA

Check out the full agenda using the links on the left of the page.

In addition, we are offering you the opportunity to explore a number of particularly complex and important issues in more depth at our 3 workshops. Seize this opportunity to benefit from 3 hours of intensive, tailored guidance on topics important to your research and your business:

• Next Generation Sequencing Analysis and Beyond
  Radically overhaul your data storage, mining and analysis strategy to get the most out of DNA sequencing technology for your research with Dr Michele Clamp, Senior Scientific Consultant at BioTeam
• IT & Infrastructure Strategies for Life Science R&D
  Keep up to date with rapid progress in development of next-gen lab instruments and ensure you capitalize on the data opportunity by operating an efficient, scalable and agile research IT infrastructure with Chris Dagdigian, Co-founder & Principal Consultant at BioTeam
• Computational Modeling of Stratified Medicines: Tools for Scientists, Executives and Policy Makers
  Learn how modeling approaches identify critical factors determining the economic viability of a stratified medicine and how this can help decision making about stratified medicines in your organization with Mark Trusheim from MIT and former, Special Government Employee at the FDA

More information can be found using the workshop links to the left of the page.

Who's the meeting for?

This meeting has been designed to provide invaluable information to drug developers and technology leaders to find the best ways of providing front-line support to drug developers through IT and informatics, including those involved in the fields of:

• R&D IT
• R&D strategy
• Computational biology
• Technology
• Informatics
• Drug discovery
• Drug design
• Portfolio management
• Decision support
• Information systems
• Systems biology
• Modeling and Simulation
• Knowledge discovery

All will benefit from this frank and open discussion of the latest computational approaches that will accelerate progress in disease treatment development.